Skip to main content

FDA Listing Inc.

FDA Listing Logo

FDA LISTING INC: EXPERIENCED ADVISORS FOR FULL-SERVICE FDA REGISTRATION & COMPLIANCE

+1 212 444 8202

U.S. FDA Registration

& Labeling Compliance Assistance

FDA Skin Protectant Monograph M016

FDA Skin Protectant Monograph M016 outlines conditions that may apply to over-the-counter skin protectant drug products marketed in the United States, including permitted active ingredients, concentration ranges, labeling, directions, warnings, and related compliance requirements.

FOTC Monograph M016: Skin Protectant Drug Products

Skin protectant products are OTC drug products intended to protect the skin and temporarily relieve minor skin irritation or itching. FDA Monograph M016 covers certain topical skin protectant products, including creams, ointments, lotions, gels, pastes, powders, diaper-rash products, chafing products, lip protectants, and similar topical dosage forms.


For brand owners, importers, private-label companies, and manufacturers, key compliance considerations include the active ingredient and concentration, intended use, dosage form, ingredient combinations, Drug Facts labeling, required warnings, directions for use, and FDA drug establishment registration and drug-listing requirements.

Skin Protectant Product Categories

FDA Monograph M016 may apply to skin protectant creams, ointments, lotions, gels, pastes, powders, diaper-rash products, anti-chafing products, lip protectants, calamine products, colloidal oatmeal products, and similar topical products marketed to temporarily protect the skin or relieve minor skin irritation and itching. The product format alone does not determine whether a product fits the monograph. Also review the active ingredient, concentration, intended use, dosage form, directions for use, warning statements, and labeling claims. A product’s claims should match the applicable active ingredient conditions and the finished formulation.

 

Products marketed with claims to treat psoriasis, rosacea, skin infections, wounds, burns, fungal conditions, or other specific diseases may fall under a different FDA regulatory framework. General skin protectant products should not use claims that exceed their applicable M016 conditions.

 

Colloidal oatmeal is a limited exception for eczema-related language. Products containing colloidal oatmeal may be labeled to temporarily protect and help relieve minor skin irritation and itching due to eczema, when the finished product meets the applicable M016 conditions. This does not authorize broader claims to treat, cure, or prevent eczema.

Common Skin Protectant Active Ingredients

Active Ingredient Concentration Range Common Product Terms
Zinc oxide 1% to 25% for general skin protectant uses; 25% to 40% for diaper-rash products Diaper-rash cream, zinc oxide ointment, skin protectant
Petrolatum 30% to 100% Petroleum jelly, barrier ointment, skin protectant
White petrolatum 30% to 100% White petrolatum ointment, lip protectant, barrier cream
Dimethicone 1% to 30% Barrier cream, anti-chafing product, skin protectant lotion
Allantoin 0.5% to 2% Skin protectant cream, minor skin-irritation product
Calamine 1% to 25% Calamine lotion, itch-relief lotion, skin protectant
Colloidal oatmeal 0.007% minimum; 0.003% minimum in certain mineral-oil combinations Oatmeal cream, itch-relief lotion, skin protectant
Glycerin 20% to 45% Skin protectant lotion, dry-skin protectant
Lanolin 12.5% to 50% Lanolin cream, lip protectant, skin protectant
Topical starch 10% to 98% Chafing powder, skin-protectant powder
Zinc acetate 0.1% to 2% Skin protectant cream, minor skin-irritation product
Zinc carbonate 0.2% to 2% Skin protectant cream, topical skin protectant

FDA Monograph M016 includes additional active ingredients, concentration conditions, permitted combinations, dosage-form limitations, and labeling requirements. This table provides a simplified overview of common skin protectant ingredients and does not replace a review of the complete monograph.

Key Skin Protectant Labeling Points

Review skin protectant labeling as part of the finished product’s overall compliance position. Active ingredients, concentration, intended use, dosage form, Drug Facts content, warnings, directions, principal display panel statements, and online marketing should align with the product’s applicable conditions.

Product Claims

Skin protectant claims should match the active ingredient, concentration, intended use, and finished product dosage form. Depending on the applicable monograph condition, products may be marketed to temporarily protect and help relieve minor skin irritation and itching associated with conditions such as poison ivy, poison oak, poison sumac, insect bites, minor cuts, scrapes, burns, minor skin irritations, and chafing.

 

Diaper-rash products may make claims associated with helping treat and prevent diaper rash and protecting chafed skin due to diaper rash. A product should not use broader claims for psoriasis, skin infections, fungal conditions, wound treatment, or other diseases unless those claims are supported through an appropriate regulatory pathway. Products containing colloidal oatmeal may make limited claims for temporary protection and relief of minor skin irritation and itching due to eczema when they meet the applicable M016 conditions.

Active Ingredient Statements

The Drug Facts panel should identify each active ingredient and its concentration, together with the corresponding purpose. The product name, front-label claims, and terms such as “skin protectant,” “diaper-rash cream,” “barrier ointment,” “anti-chafing,” or “itch relief” should match the product’s active ingredient and permitted intended use.

 

If a product contains more than one active ingredient, review the formulation and labeling for applicable combination conditions. Do not assume that separately permitted skin protectant active ingredients can be combined in any concentration, dosage form, or claim combination.

Warnings and Directions

Skin protectant products generally require product-specific warning statements and directions. Depending on the active ingredient and intended use, warnings may address external use only, avoiding contact with eyes, and stopping use and consulting a doctor if the condition worsens, symptoms last more than seven days, or symptoms clear up and occur again within a few days.

 

Diaper-rash products should include applicable child-safety and use warnings, including “For external use only,” “Keep out of reach of children,” and directions to stop use and ask a doctor if the condition worsens, does not improve, or lasts more than seven days.

 

Directions for diaper-rash products may include changing wet or soiled diapers promptly, cleansing the diaper area, allowing the area to dry, and applying the product liberally as often as necessary with each diaper change. Directions should match the product’s active ingredient, dosage form, intended use, and applicable age group.

Drug Facts Labeling

Skin protectant products should include appropriate Drug Facts information, including active ingredients, purpose, uses, warnings, directions, and inactive ingredients. The Drug Facts panel should correspond to the finished product that is commercially distributed.

 

Review product names, diaper-rash claims, barrier-protection claims, itch-relief claims, website content, retailer product descriptions, and advertising for consistency with the Drug Facts panel. Claims on ecommerce listings, social media, and other marketing materials should not expand the product’s permitted intended use.

FDA Monograph Information

This page provides a simplified overview of FDA OTC Monograph M016. It does not include every active ingredient, concentration range, permitted combination, dosage-form requirement, testing requirement, labeling detail, warning, direction, or FDA administrative order that may apply to a specific skin protectant product.

 

For complete and current requirements, including active-ingredient conditions and administrative orders applicable to OTC skin protectant drug products, review the related official FDA monograph resource.

FDA Skin Protectant Compliance Services

Skin protectant compliance involves more than selecting an active ingredient. A product review may include active ingredients, concentration levels, intended use, dosage form, ingredient combinations, labeling claims, Drug Facts labeling, warnings, directions, manufacturing activities, and drug-listing information.

We assist with:

  • Drug Establishment Registration
  • OTC Drug Listing
  • NDC Labeler Code
  • OTC Drug Label Review
  • Drug Master File

Need help with an FDA-regulated skin protectant product? Our team can assist with Drug Establishment Registration, OTC Drug Listing, NDC Labeler Codes, OTC Drug Label Review, and Drug Master Files.

Frequently Asked Questions (FAQ)

Generally, yes, when it is marketed to protect the skin or temporarily relieve minor skin irritation, itching, chafing, or diaper rash. The product’s claims and intended use help determine its regulatory status.
FDA Monograph M016 covers certain OTC skin protectant drug products. It includes conditions for permitted active ingredients, concentration ranges, labeling, warnings, directions, and product uses.
Yes. M016 includes zinc oxide at concentrations from 1% to 25% for general skin protectant uses and 25% to 40% for applicable diaper-rash products. The finished product must also meet the applicable labeling, warning, and directions requirements.
Products containing colloidal oatmeal may make limited claims for temporary protection and relief of minor skin irritation and itching due to eczema when they meet the applicable M016 conditions. Claims to treat psoriasis or other diseases are not covered by standard M016 skin protectant conditions.
Generally, yes. OTC skin protectant drug products should include Drug Facts information for the active ingredient, purpose, uses, warnings, directions, and inactive ingredients.
Drug establishment registration and drug listing may apply to companies that manufacture, process, package, repack, or relabel OTC skin protectant products for commercial distribution. The required listing arrangement depends on the company’s role.

_______ Related Services _______